Journal: Cancer Cell International

Article Title: Integrated profiling identifies DXS253E as a potential prognostic marker in colorectal cancer

doi: 10.1186/s12935-024-03403-4

Figure Lengend Snippet: DXS253E expression is increased in different types of tumors including colorectal cancer (CRC). A Pan-cancer analysis of DXS253E expression levels in human tumors according to the Cancer Genome Atlas (TCGA) dataset. B Expression of DXS253E in cancer and para-cancer paired tissues based on TCGA dataset. C, D Comparison of the expression levels of DXS253E in colon adenocarcinoma (COAD) (C) or rectum adenocarcinoma (READ) (D) and normal tissues from TCGA’s database. E Gene Expression Omnibus database (GEO) analysis of DXS253E expression in CRC tissues. F qRT-PCR assay of DXS253E mRNA expression levels in eight pairs of CRC and adjacent tissues from our experimental cohort. G Representative images of DXS253E expression in CRC tissues and matched normal tissues. Original magnifications 100× and 200× (inset panels). * P < 0.05, ** P < 0.01, *** P < 0.001, ns, no significance

Article Snippet: Primary antibodies were diluted to appropriate concentrations: DXS253E (1:1,000, Cat #19,909-1-AP, Proteintech), p-mTOR (1:,1000, Cat #2971, Cell Signaling Technology), mTOR (1:2,000, Cat #2983, Cell Signaling Technology), p-AKT (1:1,000; Cat #9271, Cell Signaling Technology), AKT (1:2,000; Cat #9272, Cell Signaling Technology), PKM2 (1:1,000, Cat #4053, Cell Signaling Technology), HK2 (1:2,000, Cat #2867, Cell Signaling Technology), GLUT1 (1:2,000, Cat #21,829-1-AP, Proteintech), and LDHA (1:1,000, Cat #2012, Cell Signaling Technology). β-actin (1:5,000; Cat #A1978, Sigma-Aldrich) was used as a control.

Techniques: Expressing, Comparison, Gene Expression, Quantitative RT-PCR

Journal: Cancer Cell International

Article Title: Integrated profiling identifies DXS253E as a potential prognostic marker in colorectal cancer

doi: 10.1186/s12935-024-03403-4

Figure Lengend Snippet: High DXS253E expression indicates aggressive clinical features and poor prognosis for CRC patients. A Association between DXS253E expression and clinical characteristics. B, C Effects of DXS253E level on overall survival (OS) and disease-specific survival (DSS) in COAD and READ. D Forest plot of univariate Cox regression analysis of DXS253E mRNA expression with OS and DSS in CRC with different clinicopathological features. E Forest plot of multivariate Cox regression analysis of DXS253E mRNA expression with OS and DSS in CRC with different clinicopathological features. * P < 0.05, ** P < 0.01, *** P < 0.001

Article Snippet: Primary antibodies were diluted to appropriate concentrations: DXS253E (1:1,000, Cat #19,909-1-AP, Proteintech), p-mTOR (1:,1000, Cat #2971, Cell Signaling Technology), mTOR (1:2,000, Cat #2983, Cell Signaling Technology), p-AKT (1:1,000; Cat #9271, Cell Signaling Technology), AKT (1:2,000; Cat #9272, Cell Signaling Technology), PKM2 (1:1,000, Cat #4053, Cell Signaling Technology), HK2 (1:2,000, Cat #2867, Cell Signaling Technology), GLUT1 (1:2,000, Cat #21,829-1-AP, Proteintech), and LDHA (1:1,000, Cat #2012, Cell Signaling Technology). β-actin (1:5,000; Cat #A1978, Sigma-Aldrich) was used as a control.

Techniques: Expressing

Journal: Cancer Cell International

Article Title: Integrated profiling identifies DXS253E as a potential prognostic marker in colorectal cancer

doi: 10.1186/s12935-024-03403-4

Figure Lengend Snippet: Univariable and multivariable analysis for OS in CRC patients with TCGA cohort

Article Snippet: Primary antibodies were diluted to appropriate concentrations: DXS253E (1:1,000, Cat #19,909-1-AP, Proteintech), p-mTOR (1:,1000, Cat #2971, Cell Signaling Technology), mTOR (1:2,000, Cat #2983, Cell Signaling Technology), p-AKT (1:1,000; Cat #9271, Cell Signaling Technology), AKT (1:2,000; Cat #9272, Cell Signaling Technology), PKM2 (1:1,000, Cat #4053, Cell Signaling Technology), HK2 (1:2,000, Cat #2867, Cell Signaling Technology), GLUT1 (1:2,000, Cat #21,829-1-AP, Proteintech), and LDHA (1:1,000, Cat #2012, Cell Signaling Technology). β-actin (1:5,000; Cat #A1978, Sigma-Aldrich) was used as a control.

Techniques:

Journal: Cancer Cell International

Article Title: Integrated profiling identifies DXS253E as a potential prognostic marker in colorectal cancer

doi: 10.1186/s12935-024-03403-4

Figure Lengend Snippet: Univariable and multivariable analysis for DSS in CRC patients with TCGA cohort

Article Snippet: Primary antibodies were diluted to appropriate concentrations: DXS253E (1:1,000, Cat #19,909-1-AP, Proteintech), p-mTOR (1:,1000, Cat #2971, Cell Signaling Technology), mTOR (1:2,000, Cat #2983, Cell Signaling Technology), p-AKT (1:1,000; Cat #9271, Cell Signaling Technology), AKT (1:2,000; Cat #9272, Cell Signaling Technology), PKM2 (1:1,000, Cat #4053, Cell Signaling Technology), HK2 (1:2,000, Cat #2867, Cell Signaling Technology), GLUT1 (1:2,000, Cat #21,829-1-AP, Proteintech), and LDHA (1:1,000, Cat #2012, Cell Signaling Technology). β-actin (1:5,000; Cat #A1978, Sigma-Aldrich) was used as a control.

Techniques:

Journal: Cancer Cell International

Article Title: Integrated profiling identifies DXS253E as a potential prognostic marker in colorectal cancer

doi: 10.1186/s12935-024-03403-4

Figure Lengend Snippet: Mutation and methylation analysis of DXS253E in CRC. A Alteration frequency of the DXS253E gene across various cancers analyzed using the cBioPortal web resource. B Differential somatic mutations identified in CRC between low and high DXS253E expression groups. C Correlation between DXS253E mRNA expression level and methylation level. D Kaplan-Meier survival curves showing six methylation sites in the DXS253E gene

Article Snippet: Primary antibodies were diluted to appropriate concentrations: DXS253E (1:1,000, Cat #19,909-1-AP, Proteintech), p-mTOR (1:,1000, Cat #2971, Cell Signaling Technology), mTOR (1:2,000, Cat #2983, Cell Signaling Technology), p-AKT (1:1,000; Cat #9271, Cell Signaling Technology), AKT (1:2,000; Cat #9272, Cell Signaling Technology), PKM2 (1:1,000, Cat #4053, Cell Signaling Technology), HK2 (1:2,000, Cat #2867, Cell Signaling Technology), GLUT1 (1:2,000, Cat #21,829-1-AP, Proteintech), and LDHA (1:1,000, Cat #2012, Cell Signaling Technology). β-actin (1:5,000; Cat #A1978, Sigma-Aldrich) was used as a control.

Techniques: Mutagenesis, Methylation, Expressing

Journal: Cancer Cell International

Article Title: Integrated profiling identifies DXS253E as a potential prognostic marker in colorectal cancer

doi: 10.1186/s12935-024-03403-4

Figure Lengend Snippet: Functional enrichment analysis of differentially expressed genes (DEGs) according to DXS253E expression level in CRC. A Volcano plot for DEGs between low DXS253E and high DXS253E expression groups. B Heatmap showing the top 10 DEGs between low and high DXS253E-expression groups. C GO enrichment analysis of DXS253E-associated DEGs. D KEGG enrichment analysis of DXS253E-associated DEGs. E GSEA of relevant signaling pathways in CRC tissues based on DXS253E-related DEGs. F Volcano plot of co-expressed genes correlated with DXS253E expression using the LinkedOmics web resource. G Heatmaps of the top 50 genes that are positively or negatively associated with DXS253E. H Venn diagram of the number of intersections between DXS253E DEGs and co‐expressed genes in CRC. I Enrichment analysis of overlapping genes analyzed by the Metascape web resource

Article Snippet: Primary antibodies were diluted to appropriate concentrations: DXS253E (1:1,000, Cat #19,909-1-AP, Proteintech), p-mTOR (1:,1000, Cat #2971, Cell Signaling Technology), mTOR (1:2,000, Cat #2983, Cell Signaling Technology), p-AKT (1:1,000; Cat #9271, Cell Signaling Technology), AKT (1:2,000; Cat #9272, Cell Signaling Technology), PKM2 (1:1,000, Cat #4053, Cell Signaling Technology), HK2 (1:2,000, Cat #2867, Cell Signaling Technology), GLUT1 (1:2,000, Cat #21,829-1-AP, Proteintech), and LDHA (1:1,000, Cat #2012, Cell Signaling Technology). β-actin (1:5,000; Cat #A1978, Sigma-Aldrich) was used as a control.

Techniques: Functional Assay, Expressing, Protein-Protein interactions

Journal: Cancer Cell International

Article Title: Integrated profiling identifies DXS253E as a potential prognostic marker in colorectal cancer

doi: 10.1186/s12935-024-03403-4

Figure Lengend Snippet: DXS253E expression is associated with multiple immune-related genes, and immune cell infiltration occurs in CRC. A Correlation of DXS253E with immunomodulatory genes in pan-cancer. B Heatmap of DXS253E expression with various tumor microenvironment cells in five independent datasets from the Tumor Immune Single-cell Hub (TISCH) database. C DXS253E expression in immune cells according to the Gene Expression Omnibus (GEO) GSE108989 and GSE136394 datasets. D Correlation between DXS253E and immune cell infiltration. E, F Relationship of DXS253E expression with the infiltration level of NK, NK CD56bright, eosinophil, Tcm, T helper, and Th2 cells using scatter plots (E) and box plots (F). * P < 0.05, ** P < 0.01, *** P < 0.001

Article Snippet: Primary antibodies were diluted to appropriate concentrations: DXS253E (1:1,000, Cat #19,909-1-AP, Proteintech), p-mTOR (1:,1000, Cat #2971, Cell Signaling Technology), mTOR (1:2,000, Cat #2983, Cell Signaling Technology), p-AKT (1:1,000; Cat #9271, Cell Signaling Technology), AKT (1:2,000; Cat #9272, Cell Signaling Technology), PKM2 (1:1,000, Cat #4053, Cell Signaling Technology), HK2 (1:2,000, Cat #2867, Cell Signaling Technology), GLUT1 (1:2,000, Cat #21,829-1-AP, Proteintech), and LDHA (1:1,000, Cat #2012, Cell Signaling Technology). β-actin (1:5,000; Cat #A1978, Sigma-Aldrich) was used as a control.

Techniques: Expressing, Gene Expression

Journal: Cancer Cell International

Article Title: Integrated profiling identifies DXS253E as a potential prognostic marker in colorectal cancer

doi: 10.1186/s12935-024-03403-4

Figure Lengend Snippet: DXS253E facilitates CRC cell malignant phenotype and aerobic glycolysis via the AKT/mTOR pathway. A Western blot assay of DXS253E protein expression levels in NCM460, LoVo, HCT116, RKO, SW480, and SW620 cell lines. B qRT-PCR assay of DXS253E mRNA expression levels in normal epithelial colon cell line NCM460 and CRC cell lines. C DXS253E overexpression accelerates the proliferation of RKO and HCT116 cells. D High levels of DXS253E expression enhance colony formation in CRC cells. E Overexpression of DXS253E enhances the malignant progression of RKO and HCT116 cells. Bar graphs show the number of migrated or invaded cells. F High levels of DXS253E decrease the generation of reactive oxygen species (ROS). G DXS253E overexpression elevates lactate production. H, I DXS253E regulates the level of glycolytic genes in CRC cells, including HK2, PKM2, GLUT1, and LDHA with qRT-PCR and western blot. J DXS253E overexpression in CRC cells mediates the activation of the AKT/mTOR pathway. * P < 0.05, ** P < 0.01, *** P < 0.001

Article Snippet: Primary antibodies were diluted to appropriate concentrations: DXS253E (1:1,000, Cat #19,909-1-AP, Proteintech), p-mTOR (1:,1000, Cat #2971, Cell Signaling Technology), mTOR (1:2,000, Cat #2983, Cell Signaling Technology), p-AKT (1:1,000; Cat #9271, Cell Signaling Technology), AKT (1:2,000; Cat #9272, Cell Signaling Technology), PKM2 (1:1,000, Cat #4053, Cell Signaling Technology), HK2 (1:2,000, Cat #2867, Cell Signaling Technology), GLUT1 (1:2,000, Cat #21,829-1-AP, Proteintech), and LDHA (1:1,000, Cat #2012, Cell Signaling Technology). β-actin (1:5,000; Cat #A1978, Sigma-Aldrich) was used as a control.

Techniques: Western Blot, Expressing, Quantitative RT-PCR, Over Expression, Activation Assay

Journal: Cancer Cell International

Article Title: Integrated profiling identifies DXS253E as a potential prognostic marker in colorectal cancer

doi: 10.1186/s12935-024-03403-4

Figure Lengend Snippet: DXS253E expression is increased in different types of tumors including colorectal cancer (CRC). A Pan-cancer analysis of DXS253E expression levels in human tumors according to the Cancer Genome Atlas (TCGA) dataset. B Expression of DXS253E in cancer and para-cancer paired tissues based on TCGA dataset. C, D Comparison of the expression levels of DXS253E in colon adenocarcinoma (COAD) (C) or rectum adenocarcinoma (READ) (D) and normal tissues from TCGA’s database. E Gene Expression Omnibus database (GEO) analysis of DXS253E expression in CRC tissues. F qRT-PCR assay of DXS253E mRNA expression levels in eight pairs of CRC and adjacent tissues from our experimental cohort. G Representative images of DXS253E expression in CRC tissues and matched normal tissues. Original magnifications 100× and 200× (inset panels). * P < 0.05, ** P < 0.01, *** P < 0.001, ns, no significance

Article Snippet: After heat-induced epitope retrieval, the slides were incubated with DXS253E antibody (1:100, Cat #19,909-1-AP, Proteintech) overnight at 4 °C, and subsequently exposed to an anti-rabbit antibody for 40 min and stained with fresh 3,3′-Diaminobenzidine substrate within a controlled reaction time of 1–2 min. Next, sections were counterstained with hematoxylin, rinsed to blue, dehydrated, and sealed.

Techniques: Expressing, Comparison, Gene Expression, Quantitative RT-PCR

Journal: Cancer Cell International

Article Title: Integrated profiling identifies DXS253E as a potential prognostic marker in colorectal cancer

doi: 10.1186/s12935-024-03403-4

Figure Lengend Snippet: High DXS253E expression indicates aggressive clinical features and poor prognosis for CRC patients. A Association between DXS253E expression and clinical characteristics. B, C Effects of DXS253E level on overall survival (OS) and disease-specific survival (DSS) in COAD and READ. D Forest plot of univariate Cox regression analysis of DXS253E mRNA expression with OS and DSS in CRC with different clinicopathological features. E Forest plot of multivariate Cox regression analysis of DXS253E mRNA expression with OS and DSS in CRC with different clinicopathological features. * P < 0.05, ** P < 0.01, *** P < 0.001

Article Snippet: After heat-induced epitope retrieval, the slides were incubated with DXS253E antibody (1:100, Cat #19,909-1-AP, Proteintech) overnight at 4 °C, and subsequently exposed to an anti-rabbit antibody for 40 min and stained with fresh 3,3′-Diaminobenzidine substrate within a controlled reaction time of 1–2 min. Next, sections were counterstained with hematoxylin, rinsed to blue, dehydrated, and sealed.

Techniques: Expressing

Journal: Cancer Cell International

Article Title: Integrated profiling identifies DXS253E as a potential prognostic marker in colorectal cancer

doi: 10.1186/s12935-024-03403-4

Figure Lengend Snippet: Univariable and multivariable analysis for OS in CRC patients with TCGA cohort

Article Snippet: After heat-induced epitope retrieval, the slides were incubated with DXS253E antibody (1:100, Cat #19,909-1-AP, Proteintech) overnight at 4 °C, and subsequently exposed to an anti-rabbit antibody for 40 min and stained with fresh 3,3′-Diaminobenzidine substrate within a controlled reaction time of 1–2 min. Next, sections were counterstained with hematoxylin, rinsed to blue, dehydrated, and sealed.

Techniques:

Journal: Cancer Cell International

Article Title: Integrated profiling identifies DXS253E as a potential prognostic marker in colorectal cancer

doi: 10.1186/s12935-024-03403-4

Figure Lengend Snippet: Univariable and multivariable analysis for DSS in CRC patients with TCGA cohort

Article Snippet: After heat-induced epitope retrieval, the slides were incubated with DXS253E antibody (1:100, Cat #19,909-1-AP, Proteintech) overnight at 4 °C, and subsequently exposed to an anti-rabbit antibody for 40 min and stained with fresh 3,3′-Diaminobenzidine substrate within a controlled reaction time of 1–2 min. Next, sections were counterstained with hematoxylin, rinsed to blue, dehydrated, and sealed.

Techniques:

Journal: Cancer Cell International

Article Title: Integrated profiling identifies DXS253E as a potential prognostic marker in colorectal cancer

doi: 10.1186/s12935-024-03403-4

Figure Lengend Snippet: Mutation and methylation analysis of DXS253E in CRC. A Alteration frequency of the DXS253E gene across various cancers analyzed using the cBioPortal web resource. B Differential somatic mutations identified in CRC between low and high DXS253E expression groups. C Correlation between DXS253E mRNA expression level and methylation level. D Kaplan-Meier survival curves showing six methylation sites in the DXS253E gene

Article Snippet: After heat-induced epitope retrieval, the slides were incubated with DXS253E antibody (1:100, Cat #19,909-1-AP, Proteintech) overnight at 4 °C, and subsequently exposed to an anti-rabbit antibody for 40 min and stained with fresh 3,3′-Diaminobenzidine substrate within a controlled reaction time of 1–2 min. Next, sections were counterstained with hematoxylin, rinsed to blue, dehydrated, and sealed.

Techniques: Mutagenesis, Methylation, Expressing

Journal: Cancer Cell International

Article Title: Integrated profiling identifies DXS253E as a potential prognostic marker in colorectal cancer

doi: 10.1186/s12935-024-03403-4

Figure Lengend Snippet: Functional enrichment analysis of differentially expressed genes (DEGs) according to DXS253E expression level in CRC. A Volcano plot for DEGs between low DXS253E and high DXS253E expression groups. B Heatmap showing the top 10 DEGs between low and high DXS253E-expression groups. C GO enrichment analysis of DXS253E-associated DEGs. D KEGG enrichment analysis of DXS253E-associated DEGs. E GSEA of relevant signaling pathways in CRC tissues based on DXS253E-related DEGs. F Volcano plot of co-expressed genes correlated with DXS253E expression using the LinkedOmics web resource. G Heatmaps of the top 50 genes that are positively or negatively associated with DXS253E. H Venn diagram of the number of intersections between DXS253E DEGs and co‐expressed genes in CRC. I Enrichment analysis of overlapping genes analyzed by the Metascape web resource

Article Snippet: After heat-induced epitope retrieval, the slides were incubated with DXS253E antibody (1:100, Cat #19,909-1-AP, Proteintech) overnight at 4 °C, and subsequently exposed to an anti-rabbit antibody for 40 min and stained with fresh 3,3′-Diaminobenzidine substrate within a controlled reaction time of 1–2 min. Next, sections were counterstained with hematoxylin, rinsed to blue, dehydrated, and sealed.

Techniques: Functional Assay, Expressing, Protein-Protein interactions

Journal: Cancer Cell International

Article Title: Integrated profiling identifies DXS253E as a potential prognostic marker in colorectal cancer

doi: 10.1186/s12935-024-03403-4

Figure Lengend Snippet: DXS253E expression is associated with multiple immune-related genes, and immune cell infiltration occurs in CRC. A Correlation of DXS253E with immunomodulatory genes in pan-cancer. B Heatmap of DXS253E expression with various tumor microenvironment cells in five independent datasets from the Tumor Immune Single-cell Hub (TISCH) database. C DXS253E expression in immune cells according to the Gene Expression Omnibus (GEO) GSE108989 and GSE136394 datasets. D Correlation between DXS253E and immune cell infiltration. E, F Relationship of DXS253E expression with the infiltration level of NK, NK CD56bright, eosinophil, Tcm, T helper, and Th2 cells using scatter plots (E) and box plots (F). * P < 0.05, ** P < 0.01, *** P < 0.001

Article Snippet: After heat-induced epitope retrieval, the slides were incubated with DXS253E antibody (1:100, Cat #19,909-1-AP, Proteintech) overnight at 4 °C, and subsequently exposed to an anti-rabbit antibody for 40 min and stained with fresh 3,3′-Diaminobenzidine substrate within a controlled reaction time of 1–2 min. Next, sections were counterstained with hematoxylin, rinsed to blue, dehydrated, and sealed.

Techniques: Expressing, Gene Expression

Journal: Cancer Cell International

Article Title: Integrated profiling identifies DXS253E as a potential prognostic marker in colorectal cancer

doi: 10.1186/s12935-024-03403-4

Figure Lengend Snippet: DXS253E facilitates CRC cell malignant phenotype and aerobic glycolysis via the AKT/mTOR pathway. A Western blot assay of DXS253E protein expression levels in NCM460, LoVo, HCT116, RKO, SW480, and SW620 cell lines. B qRT-PCR assay of DXS253E mRNA expression levels in normal epithelial colon cell line NCM460 and CRC cell lines. C DXS253E overexpression accelerates the proliferation of RKO and HCT116 cells. D High levels of DXS253E expression enhance colony formation in CRC cells. E Overexpression of DXS253E enhances the malignant progression of RKO and HCT116 cells. Bar graphs show the number of migrated or invaded cells. F High levels of DXS253E decrease the generation of reactive oxygen species (ROS). G DXS253E overexpression elevates lactate production. H, I DXS253E regulates the level of glycolytic genes in CRC cells, including HK2, PKM2, GLUT1, and LDHA with qRT-PCR and western blot. J DXS253E overexpression in CRC cells mediates the activation of the AKT/mTOR pathway. * P < 0.05, ** P < 0.01, *** P < 0.001

Article Snippet: After heat-induced epitope retrieval, the slides were incubated with DXS253E antibody (1:100, Cat #19,909-1-AP, Proteintech) overnight at 4 °C, and subsequently exposed to an anti-rabbit antibody for 40 min and stained with fresh 3,3′-Diaminobenzidine substrate within a controlled reaction time of 1–2 min. Next, sections were counterstained with hematoxylin, rinsed to blue, dehydrated, and sealed.

Techniques: Western Blot, Expressing, Quantitative RT-PCR, Over Expression, Activation Assay

Journal: European journal of medical research

Article Title: The impact of SLC10A3 on prognosis and immune microenvironment in colorectal adenocarcinoma.

doi: 10.1186/s40001-023-01526-4

Figure Lengend Snippet: Fig. 1 Identify SLC10A3 as a novel biomarker in colorectal cancer. A Flowchart of the present research. B SLC10A3 expression in different tumor and tumor-adjacent tissues in the TCGA database. * indicates p-value < 0.05; ** indicates p-value < 0.01; *** indicates p-value < 0.001

Article Snippet: The SLC10A3 (Proteintech, 19909-1-AP) antibody was utilized for IHC according to their protocols.

Techniques: Biomarker Discovery, Expressing

Journal: European journal of medical research

Article Title: The impact of SLC10A3 on prognosis and immune microenvironment in colorectal adenocarcinoma.

doi: 10.1186/s40001-023-01526-4

Figure Lengend Snippet: Fig. 2 Comparative analysis of SLC10A3 expression and methylation levels in colorectal cancer (CRC) and normal tissues based on the TCGA database. A SLC10A3 expression was higher in CRC than in normal tissues based on the TCGA database. B The ROC and AUC of CRC is based on the expression of SLC10A3. C–D SLC10A3 expression was higher in COAD and READ than in normal tissues based on the TCGA database. E–F the methylation levels of SLC10A3 in COAD, READ and normal tissues. *indicates p-value < 0.05; ** indicates p-value < 0.01; *** indicates p-value < 0.001. CRC colorectal cancer, READ rectal adenocarcinoma; COAD colon adenocarcinoma

Article Snippet: The SLC10A3 (Proteintech, 19909-1-AP) antibody was utilized for IHC according to their protocols.

Techniques: Expressing, Methylation

Journal: European journal of medical research

Article Title: The impact of SLC10A3 on prognosis and immune microenvironment in colorectal adenocarcinoma.

doi: 10.1186/s40001-023-01526-4

Figure Lengend Snippet: Fig. 3 The genetic alterations of SLC10A3. A Alterations summary of SLC10A3 in TCGA CRC datasets. B–D Summary of SLC10A3 structural variant, mutations, and copy-number alterations. CRC colorectal cancer

Article Snippet: The SLC10A3 (Proteintech, 19909-1-AP) antibody was utilized for IHC according to their protocols.

Techniques: Variant Assay

Journal: European journal of medical research

Article Title: The impact of SLC10A3 on prognosis and immune microenvironment in colorectal adenocarcinoma.

doi: 10.1186/s40001-023-01526-4

Figure Lengend Snippet: Fig. 4 High-expressional SLC10A3 affects the prognosis of CRC patients. A The OS of CRC patients between low and high-expressional groups. B The DSS of CRC patients between low and high-expressional groups. C The PFI of CRC patients between low and high-expressional groups. D–E The survival analysis of SLC10A3 high expression and low expression in COAD and READ based on the TIMER database. F SLC10A3 expression in CRC patients was analyzed based on the tumor metastasis. G–H Nomogram to predict the COAD survival possibility among 1 year, 3 years and 5 years, including age, gender, TNM stage, tumor stage, and risk score. CRC, colorectal cancer; READ, rectal adenocarcinoma; COAD, colon adenocarcinoma. HR hazard ratio, OS overall survival, DSS disease-special survival, PFI progress-free interval

Article Snippet: The SLC10A3 (Proteintech, 19909-1-AP) antibody was utilized for IHC according to their protocols.

Techniques: Expressing

Journal: European journal of medical research

Article Title: The impact of SLC10A3 on prognosis and immune microenvironment in colorectal adenocarcinoma.

doi: 10.1186/s40001-023-01526-4

Figure Lengend Snippet: Fig. 5 Correlation of immune cell infiltration, chemokines and SLC10A3 expression in CRC patients. A Relationships among infiltration levels of 24 immune cell types and SLC10A3 expression profiles by Spearman’s analysis in CRC. B–E The infiltration levels of Treg cells, CD8 + cells, NK cells, and T cells in the high- and low-SLC10A3 expression groups in CRC. F–G SLC10A3 expression is related to immune infiltration levels in COAD and READ through TIMER. H The relationship between chemokines and SLC10A3 expression in COAD and READ. CRC colorectal cancer; READ rectal adenocarcinoma, COAD colon adenocarcinoma. *p-value < 0.05; **p-value < 0.01; ***p-value < 0.001

Article Snippet: The SLC10A3 (Proteintech, 19909-1-AP) antibody was utilized for IHC according to their protocols.

Techniques: Expressing

Journal: European journal of medical research

Article Title: The impact of SLC10A3 on prognosis and immune microenvironment in colorectal adenocarcinoma.

doi: 10.1186/s40001-023-01526-4

Figure Lengend Snippet: Fig. 6 Correlation analysis of SLC10A3 and cancer-associated fibroblasts in COAD and READ. A, C The association of SLC10A3 and cancer-associated fibroblast in COAD (p-value = 1.02e−04) and READ (p-value = 5.07e-03) by EPIC. B, D The correlation analysis between the SLC10A3 expression and the expression levels of VIM, ACAT2 in the TCGA dataset. READ rectal adenocarcinoma, COAD colon adenocarcinoma

Article Snippet: The SLC10A3 (Proteintech, 19909-1-AP) antibody was utilized for IHC according to their protocols.

Techniques: Expressing

Journal: European journal of medical research

Article Title: The impact of SLC10A3 on prognosis and immune microenvironment in colorectal adenocarcinoma.

doi: 10.1186/s40001-023-01526-4

Figure Lengend Snippet: Fig. 7 Correlation analysis between SLC10A3 and immune checkpoint factors in CRC. A–F The correlation analysis between the SLC10A3 expression and the expression levels of PMS1, RAD21, DNA2, MLH3, MLH1, PMS2, MSH2, MSH6 and MSH4 in the TCGA-CRC dataset

Article Snippet: The SLC10A3 (Proteintech, 19909-1-AP) antibody was utilized for IHC according to their protocols.

Techniques: Expressing

Journal: European journal of medical research

Article Title: The impact of SLC10A3 on prognosis and immune microenvironment in colorectal adenocarcinoma.

doi: 10.1186/s40001-023-01526-4

Figure Lengend Snippet: Fig. 8 Screening DEGs and constructing functional analysis between SLC10A3 high-expressional group and SLC10A3 low-expressional group. A Volcano plots of DEGs between the expression of SLC10A3-high and SLC10A3-low in CRC samples. B GO and KEGG analysis among DEGs in CRC as a circle graph. C GSEA analysis of DEGs between SLC10A3-high and SLC10A3-low in CRC samples. CRC colorectal cancer

Article Snippet: The SLC10A3 (Proteintech, 19909-1-AP) antibody was utilized for IHC according to their protocols.

Techniques: Functional Assay, Expressing

Journal: European journal of medical research

Article Title: The impact of SLC10A3 on prognosis and immune microenvironment in colorectal adenocarcinoma.

doi: 10.1186/s40001-023-01526-4

Figure Lengend Snippet: Fig. 9 High expression of SLC10A3 predicts poor prognosis in CRC patients. A IHC analysis of SLC10A3 expression in a CRC patient tissue array (n = 72). SLC10A3 levels in cancer tissues and corresponding normal tissues. Representative images are shown. Scale bars = 100 μm. B IHC scores of SLC10A3 in human CRC tissues and adjacent tissues. C The percent of high and low SLC10A3 expression in CRC patients (normal and cancer tissues). D ROC curve with corresponding AUC value for SLC10A3 when classifying cancer from the mucosa. E–F SLC10A3 expression was positively associated with tumor relapse (R) and metastasis (M). G–H High SLC10A3 expression predicted low OS (HR = 2.23, p-value = 0.022) and DFS (HR = 2.24, p-value = 0.026). Data were shown as mean and standard deviation from three independent experiments. Data are means ± SDs. *, p-value < 0.05; **, p-value < 0.01; ***, p-value < 0.001. CRC colorectal cancer

Article Snippet: The SLC10A3 (Proteintech, 19909-1-AP) antibody was utilized for IHC according to their protocols.

Techniques: Expressing, Standard Deviation